Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.841 USD | -3.33% | +0.24% | +64.90% |
06/05 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
10/04 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.90% | 1.19Cr | |
+9.42% | 11TCr | |
+11.84% | 11TCr | |
-14.15% | 2.18TCr | |
-1.05% | 2.2TCr | |
-5.29% | 1.92TCr | |
-38.29% | 1.77TCr | |
-4.16% | 1.81TCr | |
+7.99% | 1.43TCr | |
+36.24% | 1.24TCr |
- Stock Market
- Equities
- CMMB Stock
- News Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Secures FDA Approval tor Phase 2 Trial of CM-101 for Systemic Sclerosis; Shares Climb